Altimmune, Inc. (ALT)
NASDAQ: ALT · IEX Real-Time Price · USD
7.70
-0.34 (-4.23%)
At close: May 21, 2024, 4:00 PM
7.65
-0.05 (-0.65%)
After-hours: May 21, 2024, 7:55 PM EDT

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.

Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.
Altimmune logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Dr. Vipin K. Garg Ph.D.

Contact Details

Address:
910 Clopper Road, Suite 201s
Gaithersburg, Maryland 20878
United States
Phone (240) 654-1450
Website altimmune.com

Stock Details

Ticker Symbol ALT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326190
CUSIP Number 02155H200
ISIN Number US02155H2004
Employer ID 20-2726770
SIC Code 2834

Key Executives

Name Position
Dr. Vipin K. Garg Ph.D. President, Chief Executive Officer and Director
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS Chief Medical Officer
Raymond M. Jordt M.B.A. Chief Business Officer
Richard I. Eisenstadt M.B.A. Chief Financial Officer
Bertrand Georges Ph.D. Chief Technology Officer
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer
Tony Blandin B.S. Vice President of Quality and Compliance Management
Andrew Shutterly M.S. Corporate Controller

Latest SEC Filings

Date Type Title
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2024 10-K Annual Report
Mar 27, 2024 8-K Current Report
Mar 5, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals